Navigation Links
Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
Date:4/28/2011

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

http://www.reportlinker.com/p0487249/Advanced-Lung-Cancer-with-EGFR-Mutation-Positive-Adenocarcinoma.html

Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:

• Decisions in treatment and tests through disease stages

• Factors influencing their decisions

• Barriers to optimal patient care

• Confidence in treatment

Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients

• Access the most up-to-date prescribing trends

• Gain actionable data for developing and improving your market strategies

• Pinpoint needs of your target audience

• Focus resources to maximize the effectiveness of your budget

• Understand where your product fits

• Understand where your competitor's product fits

• Design messages to advance brand performance

Table of Contents

Executive Summary - US Oncologist Survey5

Optimizing Treatment of Advanced Lung Cancer:5

Chapter 1: Introduction6

Table 1: Treatment Options in Advanced Lung Cancer6

Chapter 2: Respondent Demographics8

Table 2: Eligibility Criteria for Survey Participation8

Figure 2.1 Gender of Survey Respondents8

Figure 2.2 Years Since Medical School Graduation9

Figure 2.3 Practice Settings9

Figure 2.4 Practices in NCI Cancer Centers10

Figure 2.5 Geographic Settings10

Figure 2.6 Survey Respondents by State's Lung Cancer Mortality11

Figure 2.7 Number of Physicians in Practice Groups12

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen12

Chapter 3: Treatment of an EGFR Mutation Positive Adenocarcinoma13

Figure 3.1 First line chemotherapy regimen13

Figure 3.2 Factors influencing treatment decision14

Figure 3.3 Confidence in treating patient to an optimal outcome16

Figure 3.4 Sequence of treatment choices17

Figure 3.5 Factors influencing treatment decision18

Figure 3.6 Barriers to management of advanced lung cancer20

Chapter 4: Summary23

Appendix A: Survey Instrument24

Companies mentioned

Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Glaxo Smith Kline, Pfizer, Sanofi-aventis

To order this report:

: Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales Overview
2. Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify
3. Reportlinker Adds Pharmaceutical Key Trends 2011 - Biosimilar Market Overview
4. Reportlinker Adds Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry
5. Reportlinker Adds Forecast Insight: Antibacterials
6. Reportlinker Adds Global Cardiovascular Surgery Devices Market Trends and Future Forecast (2009 - 2014)
7. Reportlinker Adds European Smart Homes and Assisted Living Market (2010-2015)
8. Reportlinker Adds The Outlook for Pharmaceuticals in Latin America
9. Reportlinker Adds Global Respiratory Care Devices Market (2010 - 2015)
10. Reportlinker Adds Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market 2011
11. Reportlinker Adds Epidemiology: Sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Maxor National Pharmacy Services, LLC ("Maxor"), ... has named Leah Bailey as General Counsel.  Bailey ... the company. With more than 13 years ... years focused on health care, Bailey joins the Maxor ... Prime, Bailey advised the PBM, Specialty, and Mail Order ...
(Date:3/29/2017)... 2017 Varian Medical Systems (NYSE: VAR ... second quarter of fiscal year 2017 following the close of ... will be followed by a teleconference available to all interested ... link to the conference call webcast will be available on ... teleconference call and replay: ...
(Date:3/29/2017)...  Spiral Therapeutics, Inc. today announced the signature ... for the worldwide exclusive rights to Bionure,s lead ... of otolaryngology for aggregate payments of up to ... provides Spiral with the option to license two ... Under the terms of the agreement, Spiral will ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, ... prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , ... as the visionary leader in the training of physicians, scientists, and members of ...
(Date:3/29/2017)... ... 29, 2017 , ... The Wall Centre Dental team is ... from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain veneers, ... esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton Reskovich ...
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... Mich. (PRWEB) , ... March ... ... and Manufacturer Alliance (GRMA) is growing as it continues developing an ANSI-approved, ... supplement industry. The organization, which plans to publish the first ANSI-approved GMP ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, ... diagramming network and data center assets and audio-video devices has recently updated its ... equipment shapes for free and download shapes and stencils from http://www.VisioStencils.com. ...
Breaking Medicine News(10 mins):